RSVI-301
Diabetes (with planned expansion to Obesity, NAFLD, GI disorders)
Pre-clinicalActive
Key Facts
Indication
Diabetes (with planned expansion to Obesity, NAFLD, GI disorders)
Phase
Pre-clinical
Status
Active
Company
About RosVivo Therapeutics
RosVivo Therapeutics is a preclinical biotech developing a novel microRNA (miRNA) drug platform targeting large metabolic disease markets, including diabetes and obesity. The company's lead programs, RSVI-301 and RSVI-302, are based on foundational research published in high-impact journals and are advancing toward clinical trials. Led by a founder with deep scientific expertise and a CEO with extensive commercial experience, RosVivo is positioned to translate its academic discoveries into potential therapeutics, though it faces significant development and financing risks common to early-stage drug developers.
View full company profile